Medical Patent Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Patent Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Nanotechnology
Arrowhead to Form New Nanomedicine Subsidiary and Acquire Nanotherapeutics Company, C Sixty, Inc.
April 11th, 2007
Arrowhead Research Corporation (NASDAQ:ARWR) announced that it has formed a new wholly-owned subsidiary and has agreed to acquire the assets, as well as the name, of C Sixty, Inc. (C-60), a company pioneering the development of new drugs based on buckministerfullerenes (also known as fullerenes or buckyballs). The new subsidiary joins Arrowhead as its third focused on nanomedicine. Arrowhead operates two other majority owned subsidiaries commercializing nanotherapeutics. Calando Pharmaceuticals is a leading RNAi company specializing in the design and delivery of siRNA therapeutics. Insert Therapeutics is commercializing drug-delivery-enhanced small-molecule therapeutics...
Source: Medical Patent Law Weekly (2007-04-11)
|
